Shaw, 144 patient antiandrogen prophylaxis PSM study: 6% fewer cases [p=0.006] https://c19p.org/shawaa
copied to clipboard
COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients
et al., Journal of Drugs in Dermatology, doi:10.36849/JDD.5843
PSM retrospective 144 alopecia patients in the USA, showing no significant difference in COVID-19 cases with anti-androgen use. The supplemental appendix is not available.
|
risk of case, 6.0% lower, OR 0.94, p = 0.006, treatment 47, control 97, adjusted per study, propensity score matching, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Shaw et al., 7/1/2021, retrospective, USA, North America, peer-reviewed, 10 authors, study period 1 March, 2020 - 15 May, 2020.
Contact:
Kristen.LoSicco@nyulangone.org.
shaw
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.